文献速递慢性静脉疾病

810nm裸光纤大隐静脉腔内激光消融后长期临床复发风险观察

Long Term Risk of Clinical Recurrence following Endovenous Laser Ablation of the Great Saphenous Vein with 810 nm Laser Bare Tip Fibre: An Observational Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-04-02

本研究为单中心观察性研究,纳入543例C2期大隐静脉反流患者,成功行EVLA后中位随访6.0年,10年临床复发率为47.6%(95%CI 42.5-52.1%)。

要点

  • EVLA术后10年临床复发率约47.6%,近半数患者需再治疗。
  • 术后6个月内追加治疗与更高复发风险相关,提示治疗需求未满足。
  • 该复发率高于同期追加治疗及全程消融反流大隐静脉的报道。

核心结论

  • 大隐静脉EVLA术后10年内约半数患者出现临床复发,高于同期追加治疗和全程消融的报道。

研究设计与样本

  • 单中心观察性研究,纳入543例C2期大隐静脉反流患者,中位随访6.0年(IQR 1.3-10.3)。

主要发现

  • 210例患者出现临床复发,估计10年复发率为47.6%(95%CI 42.5-52.1%)。

关键数值与推荐

  • 临床复发定义为EVLA后至少6个月因治疗腿静脉曲张症状主动寻求再治疗。
  • EVLA自膝下10-15 cm开始,术后3个月超声确认闭塞。

临床怎么用

  • 应向患者告知EVLA术后10年近半数需再治疗的长期风险。
  • 术后早期追加治疗可能提示治疗需求未满足,需加强随访评估。

局限性

  • 单中心观察性设计,复发识别部分依赖电话调查,可能存在信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Varicose veins are highly prevalent and most patients present with great saphenous vein (GSV) reflux. Treatment of truncal venous reflux is the cornerstone in the management of C2 disease. Endovenous laser ablation (EVLA) is widely accepted as the preferred treatment. This study aimed to estimate the long term risk of clinical recurrence in the treated leg after successful EVLA of the GSV. METHODS: This single centre, observational study included patients with C2 varicose veins in whom refluxing GSV was diagnosed. EVLA was performed from 10 - 15 cm below the knee and occlusion was confirmed with duplex after 3 months. Additional treatment after EVLA was always in a staged approach. Clinical recurrence was defined as a patient actively seeking re-treatment at least 6 months after EVLA for symptoms due to varicose veins in the treated leg. Recurrence was identified through electronic health records or, when not documented, by telephonic survey. RESULTS: The study included 543 patients with a median follow up of 6.0 (interquartile range 1.3, 10.3) years. The mean age at treatment was 52.8 ± 13.3 years and 79.2% were women. Clinical recurrence occurred in 210 patients, with an estimated 10 year recurrence rate of 47.6% (95% confidence interval 42.5 - 52.1%). Additional therapy within 6 months following EVLA was associated with a hazard ratio of 1.31 (95% confidence 0.99 - 1.72; p = .055), adjusted for age and sex. CONCLUSION: Clinical recurrence after EVLA of the GSV occurred in approximately half of patients within 10 years of the procedure, exceeding rates reported with concomitant additional treatment and EVLA of the entire refluxing GSV. The association between early additional therapy and a higher recurrence rate suggests that it may indicate an unmet therapeutic need.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Tol MC, Vos Q, Knol-Loerakker DS, et al. Long Term Risk of Clinical Recurrence following Endovenous Laser Ablation of the Great Saphenous Vein with 810 nm Laser Bare Tip Fibre: An Observational Study. Eur J Vasc Endovasc Surg. 2026. PMID: 41935731. doi:10.1016/j.ejvs.2026.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。